Brightcove Appoints New CMO and CRO, Creates COO Position
19.12.2023 16:30:00 EET | Business Wire | Press release
Brightcove (NASDAQ: BCOV), the world’s most trusted streaming technology company, today announced two additions and a newly formed role to its executive leadership team. Kathy Klingler has been appointed Chief Marketing Officer (CMO), and Jim Norton as Chief Revenue Officer (CRO), effective January 8, 2024. Additionally, Brightcove’s current Chief Strategy and Corporate Development Officer, David Beck, is taking on an expanded role as Chief Operating Officer (COO).
“With the addition of Kathy and Jim and the evolution of David’s role, our world-class executive leadership team is poised to continue to deliver for our global customer base and drive innovation across our business,” said Brightcove CEO Marc DeBevoise. “Each of them brings an invaluable skill set from across the media, enterprise, and SaaS industries that will play a key role in our continued growth and further establish Brightcove as the world's most trusted streaming technology company.”
As CMO, Klingler will be responsible for developing and executing a global marketing strategy that leverages data, insights, creativity, and connectivity to drive growth, boost brand awareness, increase customer acquisition, and expand customer loyalty. She brings a record of global success to Brightcove, having previously held senior marketing leadership roles at large enterprise organizations in varying sectors, including Blue Cross Blue Shield of MA, Santander Bank, KPMG, Fidelity Investments, John Hancock, Kaplan Higher Education, and cybersecurity software company Rapid7. She will report directly to Brightcove CEO Marc DeBevoise.
“I am thrilled to join Brightcove to continue its unparalleled leadership in the streaming technology space,” said Klingler. “Throughout my career, I’ve prioritized crafting compelling strategies that connect with people and drive tangible results. I look forward to advancing that work with my new colleagues as we chart our company’s promising future.”
As the CRO, Norton will be responsible for Brightcove’s revenue organization, including managing global sales and customer success and driving and executing the company’s go-to-market strategy. Norton brings over 20 years of sales leadership experience in media, advertising, SaaS, and marketing technology at leading companies such as Condé Nast, AOL/Verizon, Google, Tribune Broadcasting, and Flowcode. He will report directly to DeBevoise.
“Throughout my career, I’ve had the opportunity to work across various verticals and sectors on a global scale. Brightcove represents the perfect intersection of all that I have been working towards, and I can't think of a better fit,” said Norton. “I’m enthusiastic about joining this exceptional leadership team and leveraging our heritage as the world’s most trusted streaming company as we grow global sales and revenue generation.”
David Beck has served as Chief Strategy and Corporate Development Officer and interim CMO. In addition to his current role, he has assumed new and expanded responsibilities as COO. As the Chief Operating Officer, Beck’s responsibilities include corporate development and strategy, technology and channel partnerships, data engineering, strategy and analytics, revenue and marketing operations, and ad monetization. He will be focused on advancing the execution of Brightcove’s strategy, driving operational excellence, fostering greater cross-functional collaboration throughout the organization, and leading growth and operational transformation initiatives.
For more information, visit Brightcove.com.
About Brightcove, Inc.
Brightcove creates the world’s most reliable, scalable, and secure streaming technology solutions to build a greater connection between companies and their audiences, no matter where they are or on which devices they consume content. In more than 60 countries, Brightcove’s intelligent video platform enables businesses to sell to customers more effectively, media leaders to stream and monetize content more reliably, and every organization to communicate with team members more powerfully. With two Technology and Engineering Emmy® Awards for innovation, uptime that consistently leads the industry, and unmatched scalability, we continuously push the boundaries of what video can do. Follow on LinkedIn, Twitter, Facebook, Instagram and YouTube. Visit Brightcove.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231219310496/en/
Contact information
Media Contact:
Joseph J. Nuñez
jnunez@brightcove.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi ® /Minjuvi ® ) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL30.5.2026 15:00:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP alone as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). Eligible patients had an International Prognostic Index (IPI) score of 3-5, or, for patients ≤60 years of age, an age-adjusted IPI (aaIPI) of 2-3. The oral presentation of these data is taking place at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting being held May 29 – June 2, 2026, in Chicago (Abstract #LBA7000. Session: Oral Abstract Session – Hematologic Malignancies – Lymphoma and Chronic Lymphocytic Leukemia. May 30, 4:00 – 7:00 p.m. ET [3:00 – 6:00 p.m.
Fortegra Completes Acquisition by DB Insurance29.5.2026 23:30:00 EEST | Press release
The Fortegra Group, Inc. ("Fortegra"), a global specialty insurance company, today announced the completion of its acquisition by DB Insurance Co., Ltd. ("DB"), one of Korea's leading property and casualty insurers. The transaction, announced on September 26, 2025, received all required regulatory and stockholder approvals. Fortegra will operate independently, maintaining its existing leadership team, distribution relationships, and underwriting discipline. Agents, distribution partners, and customers will continue to experience the service excellence that has defined the Fortegra experience. Richard Kahlbaugh, Chairman and CEO of Fortegra, said: "Every company eventually changes ownership. That is the nature of business. The closing of this acquisition is a starting point. As part of DB Insurance, Fortegra is positioned to expand our business geographically, enhance our capabilities and deepen our market presence in the US, Europe, the United Kingdom and Asia. Together, DB Insurance a
SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 23:01:00 EEST | Press release
Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release
NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release
Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
